United Therapeutics Corp
NASDAQ:UTHR 12:10:33 PM EDT
| Market Cap (Intraday) | 10.07B |
| Current PE | 15.96 |
| Forward PE | 13.07 |
| 2yr Forward PE | 11.87 |
| 10-Day MA | $221.24 |
| 50-Day MA | $229.13 |
| 200-Day MA | $202.69 |
United Therapeutics Corp Stock, NASDAQ:UTHR
1040 Spring Street, Silver Spring, Maryland 20910
United States of America
Phone: +1.301.608.9292
Number of Employees: 965
Description
United Therapeutics Corp. operates as a biotechnology company engaged in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It is involved in the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. The company was founded by Martine A. Rothblatt on June 26, 1996, and is headquartered in Silver Spring, MD.